Comparison of Efficacy of Oral Lacosamide Versus Oral Topiramate in Young Adults  with Chronic Migraine

Nabeel Tahir Butt; Muhammad  Usman; Abdul Hameed  Bhatti; Farah  Ahsan; Rizwan  Azam; Kashif Raza  Kazmi

doi:10.51253/pafmj.v75i4.10850

Authors

Nabeel Tahir Butt Department of Anesthesia, Combined Military Hospital, Rahim Yar Khan/National University of Medical Sciences (NUMS) Pakistan
Muhammad Usman Department of Medicine, Combined Military Hospital, Rahim Yar Khan/National University of Medical Sciences (NUMS) Pakistan
Abdul Hameed Bhatti Department of Anesthesia, Combined Military Hospital, Rahim Yar Khan/National University of Medical Sciences (NUMS) Pakistan
Farah Ahsan Department of Pathology, Combined Military Hospital, Rahim Yar Khan/National University of Medical Sciences (NUMS) Pakistan
Rizwan Azam Department of Medicine, Combined Military Hospital, Rahim Yar Khan/National University of Medical Sciences (NUMS) Pakistan
Kashif Raza Kazmi Combined Military Hospital, Rahim Yar Khan/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75i4.10850

Keywords:

Chronic, Lacosamide, Migraine, Topiramate

Abstract

Objective: To compare the efficacy of the new anti-epileptic drug Lacosamide vs conventional treatment with Topiramate for the treatment of young adults presenting with chronic migraine.

Study Design: Randomized controlled trial.

Place and Duration of Study: Department of Anesthesia (Pain clinic) and Department of Medicine, Combined Military Hospital Rahim Yar Khan, Pakistan from Jan to Jun 2023.

Methodology: The patients were divided into two groups, Group-T (n=145) and Group-L (n=145). Patients in Group-T received oral Topiramate at a dose of 50 mg twice a day while Group-L received oral Lacosamide at a dose of 100 mg twice a day. All the participants received the drug regime in both groups for a period of three months. Primary variables observed were improvement in the quality of life and migraine free days during therapy due to the disease according to the MIDAS (Migraine disability assessment) scoring system before and after 90 days of treatment.

Results: While observing the primary variables, median MIDAS (Migraine Disability Assessment) scores before therapy were 11.00 (IQR=2.00) in Group-L versus 11.00 (IQR=3.00) in Group-T (p=0.743). The same median scores were 6.00 (IQR=1.00) in Group-L versus 8.00 (IQR=0.00) in Group-T (p<0.001). Mean days to an episode of migraine before start of therapy were 17.17±2.04 days in Group-L versus 17.06±1.99 days in Group-T (p=0.663). During therapy for 90 days, migraine free days following up to an episode of migraine were..

Conclusion: Treatment with oral Lacosamide resulted increased migraine free days with a more conducive adverse effect profile.

Downloads

Download data is not yet available.

References

Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M, et al. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol 2022; 23(12): 800605.

https://doi.org/10.3389/fneur.2021.800605

2. Choudry H, Ata F, Alam MNN, Ruqaiya R, Suheb MK, Ikram MQ, et al. Migraine in physicians and final year medical students: A cross-sectional insight into prevalence, self-awareness, and knowledge from Pakistan. World J Methodol 2022; 12(5): 414-427. https://doi.org/10.5662/wjm.v12.i5.414

3. Khan J, Al Asoom LI, Al Sunni A, Rafique N, Latif R, Al Saif S, et al. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother 2021; 139: 111557.

https://doi.org/10.1016/j.biopha.2021.111557

4. Raucci U, Boni A, Evangelisti M, Della Vecchia N, Velardi M, Ursitti F, et al. Lifestyle modifications to help prevent headache at a developmental age. Front Neurol 2021; 2(11): 618375.

https://doi.org/10.3389/fneur.2020.618375

5. Van Casteren DS, Verhagen IE, Onderwater GL, MaassenVanDenBrink A, Terwindt GM. Sex differences in prevalence of migraine trigger factors: a cross-sectional study. Cephalalgia 2021; 41(6): 643-648.

https://doi.org/10.1177/0333102420974362

6. Pearl NZ, Babin CP, Catalano NT, Blake JC, Ahmadzadeh S, Shekoohi S, et al. Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations. Adv Ther 2023; 40(9): 3626-3638. https://doi.org/10.1007/s12325-023-02586-y

7. Hu C, Zhang Y, Tan G. Advances in topiramate as prophylactic treatment for migraine. Brain Behav 2021; 11(10): e2290.

https://doi.org/10.1002/brb3.2290

8. Li J, Sun M, Wang X. The adverse-effect profile of lacosamide. Expert Opin Drug Saf 2020; 19(2): 131-138.

https://doi.org/10.1080/14740338.2020.1713089

9. Schultz L, Mahmoud SH. Is Therapeutic Drug Monitoring of Lacosamide Needed in Patients with Seizures and Epilepsy? Eur J Drug Metab Pharmacokinet 2020; 45(3): 315-349.

https://doi.org/10.1007/s13318-019-00601-8

10. Athar F, Zahid A, Farooq M, Ayyan M, Ashraf M, Farooq M, et al. Frequency of migraine according to the ICHD-3 criteria and its association with sociodemographic and triggering factors in Pakistan: A cross-sectional study. Ann Med Surg 2022; 82: 104589. https://doi.org/10.1016/j.amsu.2022.104589

11. Chia V, Bogdanov A, Yusuf A, Kallenbach L. Characteristics of migraine patients with Migraine Disability Assessment (MIDAS) scores in real-world clinical practice. Cephalalgia Reports 2020; 3: 2515816320928463.

http://doi.org/10.1177/2515816320928463

12. Fariba KA, Saadabadi A. Topiramate. Stat Pearls: 2020.

13. Carona A, Bicker J, Silva R, Fonseca C, Falcão A, Fortuna A et al. Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications. Life Sci 2021: 15; 275: 119342. https://doi.org/10.1016/j.lfs.2021.119342

14. Lionetto L, Negro A, Palmisani S, Gentile G, Fiore MRD, Mercieri M, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012; 17(3): 393-406. https://doi.org/10.1517/14728214.2012.709846

15. Yuan H, Wong K-H, Davis R, Ozudogru S. The Effect of Lacosamide on Chronic Migraine: Retrospective Analysis in a Single Center Healthcare Academic Institute 2019; 10(3): 023 http://doi.org/10.1212/WNL.92.15_supplement.P3.10-023

16. Li K-Y, Huang L-C, Chang Y-P, Yang Y-H. The effects of Lacosamide on cognitive function and psychiatric profiles in patients with epilepsy. Epilepsy Behav 2020; 113: 107580.

https://doi.org/10.1016/j.yebeh.2020.107580

17. Fong SL, Thuy Le MA, Lim KS, Khosama H, Ohnmar O, Savath S, et al. Affordability of newer antiseizure medications in Asian resource‐limited countries. Epilepsia 2023; 64(8): 2116-2125.

https://doi.org/10.1111/epi.17668

18. Asghar MA, Rehman AA, Raza ML, Shafiq Y, Asghar MA. Analysis of treatment adherence and cost among patients with epilepsy: a four‐year retrospective cohort study in Pakistan. BMC Health Serv Res 2021; 21: 1-8.

https://doi.org/10.1186/s12913-021-06085-0